Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Patient-Centered Discussions Will Be Critical to Navigate Treatment Selection in EGFR+ NSCLC

October 4th 2024

Isabel Preeshagul, DO, MBS, discusses considerations for treatment selection in the first and second line for patients with EGFR-mutated NSCLC.

FDA Approves Perioperative Nivolumab for Resectable NSCLC

October 3rd 2024

The FDA has approved nivolumab with platinum chemotherapy as neoadjuvant treatment, followed by single-agent nivolumab after surgery, in resectable NSCLC.

Dr Girard on PROs From the LUMINOSITY Trial in c-Met–Overexpressing NSCLC

October 3rd 2024

Nicolas Girard, MD, discusses PROs from the LUMINOSITY trial of Teliso-V in patients with c-Met protein–overexpressing, EGFR wild-type, nonsquamous NSCLC.

Allogeneic T-Cell Therapy Produces Efficacy at 10 Months in Stage IV Metastatic NSCLC

October 1st 2024

Treatment with Deltacel was safe and showed antitumor activity at 10 months in a patient with stage IV metastatic non–small cell lung cancer.

The OncFive: Top Oncology Articles for the Week 9/22

September 28th 2024

The FDA’s ODAC votes against the risk:benefit profile of frontline PD-1 inhibitors in select tumor types, osimertinib gains approval for select NSCLC, and more this week from OncLive.

Dr Gadgeel on Longer-Term Data for Amivantamab Plus Lazertinib in EGFR+ NSCLC

September 27th 2024

Shirish M. Gadgeel, MD, on long-term follow-up data from MARIPOSA for amivantamab plus lazertinib in first-line EGFR-mutated non–small cell lung cancer.

Dr Sands on Consolidation Durvalumab as a Potential New SOC for LS-SCLC After Chemoradiation

September 27th 2024

Jacob Sands, MD, discusses consolidation therapy durvalumab as a new standard of care in limited-stage small cell lung cancer.

Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need

September 27th 2024

Dr. Xiuning Le highlights real-world data on therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations, emphasizing the need for improved treatments, at ESMO Congress 2024.

Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC

September 27th 2024

Jacob Sands, MD, presents promising early-phase trial results for obrixtamig, a novel DLL3-targeting T-cell engager, in patients with large cell neuroendocrine carcinoma of the lung (LCNEC-L), shared at ESMO Congress 2024.

FDA Approves Osimertinib for Locally Advanced, Unresectable EGFR+ NSCLC After Chemoradiation

September 25th 2024

The FDA approved osimertinib for EGFR-mutated, locally advanced, unresectable, non–small cell lung cancer after chemoradiation.

Dr Aggarwal on Data for CAN-2409 Plus Valacyclovir and Continued ICIs in NSCLC

September 25th 2024

Charu Aggarwal, MD, MPH, FASCO, on data for CAN-2409 plus valacyclovir with continued immune checkpoint inhibitors in advanced non–small cell lung cancer.

BDTX-1535 Generates Early Signals of Antitumor Activity in R/R EGFR+ NSCLC

September 23rd 2024

BDTX-1535 yielded durable clinical activity in patients with relapsed/refractory, EGFR-mutant NSCLC harboring resistance mutations.

First-Line Serplulimab Receives Positive CHMP Opinion for ES-SCLC

September 23rd 2024

The CHMP has recommended the European approval of serplulimab for the first-line treatment of extensive-stage small cell lung cancer.

The OncFive: Top Oncology Articles for the Week of 9/15

September 21st 2024

Adjuvant ribociclib receives FDA approval for HR+ breast cancer, AMG 193 elicits responses in MTAP-deleted solid tumors, and more this week from OncLive.

Fox Chase Cancer Center Researchers Examine Perceptions of Smoking Stigma Among African American/Black Populations

September 20th 2024

In research published in Nicotine & Tobacco Research, lead author Charnita Zeigler-Johnson, PhD, MPH, Associate Director of Community Outreach and Engagement, studied the prevalence of smoking stigma among the African American/Black community.

FDA Approves Amivantamab Plus Chemo for EGFR+ Advanced NSCLC After an EGFR Inhibitor

September 19th 2024

The FDA has approved amivantamab plus chemotherapy for locally advanced or metastatic NSCLC harboring select EGFR mutations after an EGFR TKI.

Experts Highlight Top Findings From the 2024 IASLC World Conference on Lung Cancer

September 18th 2024

Experts across the lung cancer treatment space impart their key takeaways from research shared at the 2024 IASLC World Conference on Lung Cancer.

Dr Wolf on Unmet Needs With Surgery in Mesothelioma Treatment

September 18th 2024

Andrea Wolf, MD, MPH, discusses challenges in conducting randomized controlled trials to assess the role of surgery in the treatment of mesothelioma.

FDA Approves Pembrolizumab Plus Chemo for Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma

September 17th 2024

The FDA has approved frontline pembrolizumab plus chemotherapy for use in unresectable advanced or metastatic malignant pleural mesothelioma.

Dr Gadgeel on Long-Term Data With Amivantamab/Lazertinib in EGFR+ Advanced NSCLC

September 17th 2024

Shirish M. Gadgeel, MD, discusses long-term follow-up data from the MARIPOSA study for patients with EGFR-positive advanced non–small cell lung cancer.